A Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile associated diarrhea successfully met its primary objective. The top-line results from the recently completed multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated a statistically significant reduction in recurrences of CDAD when compared with placebo.